Key result
Celiprolol is a unique selective adrenoceptor modulator that may reduce mechanical stress on arterial walls and prevent life-threatening vascular complications in patients with vascular Ehlers-Danlos syndrome.
Why the study?
Does celiprolol reduce arterial events in patients with vascular type Ehlers-Danlos syndrome?
Does celiprolol reduce arterial events in patients with vascular type Ehlers-Danlos syndrome?
Celiprolol, a unique beta-blocker with partial beta-2 agonist activity, shows promise in reducing arterial events in patients with vascular type Ehlers-Danlos syndrome.
Answers are grounded in this paper and cite their sources.
Proposed celiprolol indication in vascular Ehlers-Danlos syndrome is hypothesis-generating; randomized trials needed before any practice consideration.
Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties and is indicated for those uses in various countries around the world. In the United States, however, the proposed indication for this drug will be for the treatment of vascular type Ehlers-Danlos syndrome, a rare connective tissue disorder characterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure, celiprolol may reduce the mechanical stress on collagen fibers within the arterial wall and be of benefit in patients with vascular type Ehlers-Danlos syndrome. The largest investigation of celiprolol in vascular Ehlers-Danlos syndrome was prematurely terminated due to significant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol, therefore, represents a β-blocker that is unique from others in its class in both its pharmacology and clinical applications.
No takes yet. Share an insight, caveat, or question.
Nawarskas et al. (2017) conducted a review in Vascular Ehlers-Danlos syndrome (vEDS) and cardiovascular disorders. Celiprolol was evaluated. Celiprolol is a unique selective adrenoceptor modulator that may reduce mechanical stress on arterial walls and prevent life-threatening vascular complications in patients with vascular Ehlers-Danlos syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: